Caribou Biosciences price target lowered to $32 from $36 at Oppenheimer

Oppenheimer analyst Mark Breidenbach lowered the firm’s price target on Caribou Biosciences to $32 from $36 and keeps an Outperform rating on the shares following the Q4 earnings report. Management committed to presenting at least one clinical update from its ongoing ANTLER study in 2H23, aiming to deliver results from 15+ B-NHL patients with greater than or equal to 6 months follow-up from up to three dosing cohorts, the analyst tells investors in a research note.